Table 4.

Comparison of the clinical features and outcomes between subgroups with different antiplatelet agents.

Characteristic	Aspirin (n = 33)	Clopidogrel (n = 10)	Aspirin combined with clopidogrel (n = 10)	p-value
Age at symptom onset (years)	47 ± 12	46 ± 10	52 ± 9	0.393
Age at diagnosis (years)	48 ± 12	46 ± 10	52 ± 10	0.463
Female-to-male ratio	0.8	0.7	0.4	0.682
Vascular risk factors
Hypertension	14 (42.4%)	3 (30.0%)	6 (60.0%)	0.393
Diabetes mellitus	4 (12.1%)	1 (10.0%)	3 (30.0%)	0.339
Hyperlipidemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1.000
Active smoking	9 (27.3%)	3 (30.0%)	4 (40.0%)	0.745
Alcohol consumption	6 (18.2%)	2 (20.0%)	5 (50.0%)	0.115
Past history of stroke or TIA	7 (21.2%)	0 (0.0%)	1 (10.0%)	0.229
Family history of MMD	2 (6.1%)	0 (0.0%)	0 (0.0%)	0.533
mRS score at baseline
0–2	26 (78.8%)	8 (80.0%)	9 (90.0%)	0.726
>2	7 (21.2%)	2 (20.0%)	1 (10.0%)
Angiography findings
Bilateral	31 (93.9%)	8 (80.0%)	9 (90.0%)	0.417
Suzuki stage ≥III	29 (87.9%)	8 (80.0%)	9 (90.0%)	0.769
Intracranial aneurysm	1 (3.0%)	1 (10.0%)	2 (20.0%)	0.195
Clinical manifestation
TIA	8 (24.2%)	3 (30.0%)	4 (40.0%)	0.734
Lacunar infarction	2 (6.1%)	0 (0.0%)	0 (0.0%)
Cerebral infarction	23 (69.7%)	7 (70.0%)	6 (60.0%)
Follow-up (months)	36.9 ± 22.6	31.8 ± 17.1	35.4 ± 13.4	0.787
Outcomes
Future ischemic stroke	2 (6.1%)	0 (0.0%)	1 (10.0%)	0.618
Poor functional status	8 (24.2%)	3 (30.0%)	1 (10.0%)	0.530
Serious bleeding event	2 (6.1%)	0 (0.0%)	0 (0.0%)	0.533